Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.66 |
| ▸ | RAB9A | P51151 | 8/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.66 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | CASP1 | P29466 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3081119 | 0.84 | CNR2 (0.75) | NPC1RAB9ASMN1; SMN2AKR1C3MAPT | |
| SCHEMBL3075247 | 0.84 | MAPT (0.77) | NPC1RAB9ASMN1; SMN2MAPTLMNA | |
| SCHEMBL3075093 | 0.82 | CNR2 (0.55) | NPC1RAB9AAKR1C3MAPTLMNA | |
| SCHEMBL809829 | 0.81 | RAB9A (1.00) | NPC1RAB9ASMN1; SMN2MAPTLMNA | |
| Hydrogen Sulfide SCHEMBL11606123 | 0.79 | RAB9A (0.97) | NPC1RAB9ASMN1; SMN2MAPTLMNA | |
| SCHEMBL4152060 | 0.79 | MAPT (0.69) | NPC1RAB9ASMN1; SMN2MAPTLMNA | |
| SCHEMBL24937772 | 0.78 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2MAPTLMNA | |
| SCHEMBL18711482 | 0.77 | NPC1 (0.74) | NPC1RAB9ASMN1; SMN2MAPTLMNA | |
| SCHEMBL8526236 | 0.76 | RAB9A (0.73) | NPC1RAB9ASMN1; SMN2MAPTLMNA | |
| SCHEMBL3088185 | 0.76 | MAPT (0.64) | AKR1C3MAPTLMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | claimed |
| EP-2215080-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2010-08-11 | — | — | EP | claimed |
| WO-2009055357-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | WO | claimed |
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| EP-2215080-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009055357-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009055357-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | CNR1, CNR2, BDKRB2 | NPC1 1695/4885RAB9A 3016/4885SMN1; SMN2 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.